CDNA
Price
$19.23
Change
-$0.06 (-0.31%)
Updated
Jun 27 closing price
Capitalization
548.33M
43 days until earnings call
RYLPF
Price
$24.37
Change
+$0.66 (+2.78%)
Updated
Jun 27 closing price
Capitalization
19.18B
Interact to see
Advertisement

CDNA vs RYLPF

Header iconCDNA vs RYLPF Comparison
Open Charts CDNA vs RYLPFBanner chart's image
CareDx
Price$19.23
Change-$0.06 (-0.31%)
Volume$2.03M
Capitalization548.33M
Koninklijke Philips N.V
Price$24.37
Change+$0.66 (+2.78%)
Volume$187
Capitalization19.18B
CDNA vs RYLPF Comparison Chart in %
Loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYLPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDNA vs. RYLPF commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a Buy and RYLPF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (CDNA: $19.23 vs. RYLPF: $24.37)
Brand notoriety: CDNA and RYLPF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CDNA: 167% vs. RYLPF: 1%
Market capitalization -- CDNA: $548.33M vs. RYLPF: $19.18B
CDNA [@Medical Specialties] is valued at $548.33M. RYLPF’s [@Medical Specialties] market capitalization is $19.18B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 0 FA rating(s) are green whileRYLPF’s FA Score has 1 green FA rating(s).

  • CDNA’s FA Score: 0 green, 5 red.
  • RYLPF’s FA Score: 1 green, 4 red.
According to our system of comparison, CDNA is a better buy in the long-term than RYLPF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 5 TA indicator(s) are bullish while RYLPF’s TA Score has 6 bullish TA indicator(s).

  • CDNA’s TA Score: 5 bullish, 5 bearish.
  • RYLPF’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, RYLPF is a better buy in the short-term than CDNA.

Price Growth

CDNA (@Medical Specialties) experienced а +1.00% price change this week, while RYLPF (@Medical Specialties) price change was +4.96% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.37%. For the same industry, the average monthly price growth was +1.94%, and the average quarterly price growth was +2.76%.

Reported Earning Dates

CDNA is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Medical Specialties (+2.37% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYLPF($19.2B) has a higher market cap than CDNA($548M). RYLPF YTD gains are higher at: -3.501 vs. CDNA (-10.182). CDNA has higher annual earnings (EBITDA): -84.92M vs. RYLPF (-210M). RYLPF has more cash in the bank: 968M vs. CDNA (235M). CDNA has less debt than RYLPF: CDNA (34.2M) vs RYLPF (8.22B). RYLPF has higher revenues than CDNA: RYLPF (18.4B) vs CDNA (280M).
CDNARYLPFCDNA / RYLPF
Capitalization548M19.2B3%
EBITDA-84.92M-210M40%
Gain YTD-10.182-3.501291%
P/E RatioN/A29.76-
Revenue280M18.4B2%
Total Cash235M968M24%
Total Debt34.2M8.22B0%
FUNDAMENTALS RATINGS
CDNA vs RYLPF: Fundamental Ratings
CDNA
RYLPF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
4686
PRICE GROWTH RATING
1..100
4857
P/E GROWTH RATING
1..100
8164
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RYLPF's Valuation (4) in the null industry is significantly better than the same rating for CDNA (95) in the Medical Specialties industry. This means that RYLPF’s stock grew significantly faster than CDNA’s over the last 12 months.

RYLPF's Profit vs Risk Rating (100) in the null industry is in the same range as CDNA (100) in the Medical Specialties industry. This means that RYLPF’s stock grew similarly to CDNA’s over the last 12 months.

CDNA's SMR Rating (46) in the Medical Specialties industry is somewhat better than the same rating for RYLPF (86) in the null industry. This means that CDNA’s stock grew somewhat faster than RYLPF’s over the last 12 months.

CDNA's Price Growth Rating (48) in the Medical Specialties industry is in the same range as RYLPF (57) in the null industry. This means that CDNA’s stock grew similarly to RYLPF’s over the last 12 months.

RYLPF's P/E Growth Rating (64) in the null industry is in the same range as CDNA (81) in the Medical Specialties industry. This means that RYLPF’s stock grew similarly to CDNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDNARYLPF
RSI
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
66%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
57%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
55%
MACD
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 4 days ago
60%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
55%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
52%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 4 days ago
48%
Declines
ODDS (%)
Bearish Trend 18 days ago
87%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
60%
Aroon
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
60%
View a ticker or compare two or three
Interact to see
Advertisement
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RYLPF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITGIX103.980.81
+0.79%
VY® T. Rowe Price Growth Equity I
PWJRX33.370.18
+0.54%
PGIM Jennison International Opps R
NMVLX12.000.06
+0.51%
Nuance Mid Cap Value Institutional
LVPSX92.660.37
+0.40%
ProFunds Large Cap Value Svc
BSCRX16.69-0.03
-0.18%
Brandes Small Cap Value R6

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-0.31%
VCYT - CDNA
45%
Loosely correlated
+2.13%
ILMN - CDNA
45%
Loosely correlated
+0.67%
NTRA - CDNA
44%
Loosely correlated
-0.12%
GKOS - CDNA
40%
Loosely correlated
+0.36%
A - CDNA
39%
Loosely correlated
-0.21%
More

RYLPF and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYLPF has been loosely correlated with MTD. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if RYLPF jumps, then MTD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYLPF
1D Price
Change %
RYLPF100%
+2.78%
MTD - RYLPF
38%
Loosely correlated
-0.73%
CDNA - RYLPF
28%
Poorly correlated
-0.31%
MBGNF - RYLPF
24%
Poorly correlated
N/A
SRTS - RYLPF
23%
Poorly correlated
+0.83%
WRBY - RYLPF
21%
Poorly correlated
+1.91%
More